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“Personalized medicine” is a new concept in healthcare, one aspect of which 
defines the specificity and dosage of drugs according to effectiveness and 
safety for each patient. Dosage strongly depends on the rate of metabolism 
which is primarily regulated by the activity of cytochrome P450. In addition to 
the need for a genetic characterization of the patients, there is also the necessity 
to determine the drug clearance properties of the polymorphic drug 
metabolising enzymes.It is well-recognized that patients administered a 
particular drug will exhibit significant inter-individual variability in their 
response to treatment. Unfortunately some patients will fail to respond to the 
therapy entirely, while some others will suffer dose-related side effects, 
resulting in significant costs and fatalities. For these reasons, polymorphism in 
genes encoding the drug metabolizing cytochromes P450 and flavin-containing 
monooxygenases is a very important factor that can no longer be neglected in 
the development of new drugs. Progress in the human genome analysis has 
recently made it possible to identify a patient’s cytochromes P450 make up by 
genotype analysis using the AmpliChip CYP450 Test available from Roche 
Diagnostics. However, genotyping needs a parallel enzyme-based platform 
capable of rapidly measuring a drug’s pharmacokinetics and clearance by the 
polymorphic drug metabolising enzymes typical of a given genotype, and to 
this date, such a platform is not available; this is the subject of the present 
work.	  
